Biggest company in rnai with lots of cash says: we are cutting costs as much as possible to focus on just 2 core products and will try to partner alsmost everything else we have. What does this say about possibilities of raising cash, favorable upfront payments etc?
Seems to me that the Anylyn CEO realizes the siRNA cookie tray isn't going to be passed around any again time soon. To that end he switching from a pie in the sky to a show me the money strategy. It wouldn't surprise me if he took some of the $250MM and purchased a more conventional drug in later stage trials. If you followed Millenium's history were in the same boat(different technology) and did just that. MLNM was sold for $8BB mostly because of the purchased technology.
ARWR isn't quite in the same place. They have such a low market cap that if they can produce an steady income stream of say $5MM/yr from any of the several technologies they've liscensed, that should be enough to get lift off(in my opinion)...providing it's before they run out of cash.